Global X Cloud Computing ETF vs Novo Nordisk A/S — how do they compare? Global X Cloud Computing ETF trades at $27.79, while Novo Nordisk A/S trades at $47.23 (market cap $207.85B). The key difference: Novo Nordisk A/S pays a 3.81% dividend while Global X Cloud Computing ETF pays none, and Global X Cloud Computing ETF is trading nearer its 52-week high, Novo Nordisk A/S nearer its low. Which is the better fit depends on your goals.
| CLOU | NVO | |
|---|---|---|
Sector | Sector/Thematic | Health |
52-Week High | $28.09 | $63.98 |
52-Week Low | $17.60 | $35.29 |
Market Cap | — | $207.85B |
Enterprise Value | — | $222.55B |
Dividend Yield | — | 3.81% |
Signals from Pluang's Aura AI — not financial advice
CLOU, the Global X Cloud Computing ETF, trades at $27.66, down 1.53% on the day, with a bullish technical signal from moving averages and ADX indicators. The ETF provides diversified exposure to cloud computing stocks, with recent news highlighting long-term growth potential beyond AI hype, driven by strong holdings like Snowflake and Datadog. RSI levels above 80 indicate overbought conditions, suggesting near-term caution.
The outlook for CLOU remains positive due to structural growth in cloud adoption, though high RSI readings and competition from other cloud ETFs pose risks. Investor sentiment is buoyed by resilient subscription revenues and diversification benefits, but volatility in tech stocks and macroeconomic pressures could impact performance.
Novo Nordisk (NVO) trades at $46.465, down 2.65% today, with a neutral technical signal. The stock shows strong fundamentals, including a P/E of 11.62, net income margin of 35.35%, and consistent earnings beats in recent quarters. Recent news highlights competitive pressures from Eli Lilly and mixed investor reactions to Q2 2026 results, despite an upwardly revised full-year outlook.
Outlook remains positive due to robust GLP-1 drug demand and profitability, but risks include pricing pressure and competition. Analysts are predominantly bullish (57.9% buy ratings), supporting a favorable long-term view despite near-term volatility.
Trailing returns across standard periods
Latest headlines on both assets
CLOU is a thematic ETF that invests in companies leading the cloud revolution. It targets providers of SaaS, PaaS, and IaaS, including major firms like Salesforce, Akamai, and Shopify that drive modern digital infrastructure.
Read more on CLOU →With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →